NCT02221505 (Clinical Trial / LOP628)

Study Title
Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia (NCT02221505)

Trial Description
LOP628 is an antibody-drug conjugate (ADC) consisting of an anti-cKit humanized IgG1/κ antibody conjugated to a maytansine payload via a non-cleavable linker. LOP628 provides an opportunity to target cKit overexpressing tumors.

This trial is sponsored by Novartis Pharmacueticals Co[1]

Study Data

  • Condition: Leukemia
  • Interventions:
    • Drugs used in this trial
      • LOP268
  • Phase: I
  • Estimated Enrollment: 3
  • Start: December 2014
  • Estimated Study Completion: June 2020
  • Last verified: April 2016

Study Schematic 

(Coming soon)

Click here to Return to Drug map

Last Editorial review: August 24, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.